SCHEMBL905579

SCHEMBL905579

CCCCCCCCC(C[N+](C)(C)C)OP(=O)([O-])O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMPD1 P17405 3/20 0.47
SLC25A20 O43772 3/20 0.43
TP53 P04637 2/20 0.43
CYP2D6 P10635 2/20 0.43
TSHR P16473 2/20 0.43
MEN1 O00255 2/20 0.43
MAPT P10636 2/20 0.43
KMT2A Q03164 2/20 0.43
KDM4E B2RXH2 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C9 P11712 1/20 0.43
NFKB1 P19838 1/20 0.43
CYP2C19 P33261 1/20 0.43
THPO P40225 1/20 0.43
HIF1A Q16665 1/20 0.43
HSD17B10 Q99714 1/20 0.43
SLC6A5 Q9Y345 1/20 0.43
FDPS P14324 3/20 0.43
S1PR2 O95136 5/20 0.41
S1PR1 P21453 5/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31485403 1.00 SMPD1 (0.47) SMPD1SLC25A20TP53CYP2D6TSHR
SCHEMBL62053 1.00 SMPD1 (0.47) SMPD1SLC25A20TP53CYP2D6TSHR
SCHEMBL4638950 1.00 SMPD1 (0.47) SMPD1SLC25A20TP53CYP2D6TSHR
SCHEMBL418811 1.00 SMPD1 (0.47) SMPD1SLC25A20TP53CYP2D6TSHR
SCHEMBL60425 1.00 SMPD1 (0.47) SMPD1SLC25A20TP53CYP2D6TSHR
SCHEMBL60847 1.00 SMPD1 (0.47) SMPD1SLC25A20TP53CYP2D6TSHR
SCHEMBL2695073 1.00 SMPD1 (0.47) SMPD1SLC25A20TP53CYP2D6TSHR
SCHEMBL632448 1.00 SMPD1 (0.47) SMPD1SLC25A20TP53CYP2D6TSHR
SCHEMBL2693658 1.00 SMPD1 (0.47) SMPD1SLC25A20TP53CYP2D6TSHR
SCHEMBL52689 1.00 SMPD1 (0.47) SMPD1SLC25A20TP53CYP2D6TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9513253-B2 Droplet actuators and techniques for droplet-based enzymatic assays ADVANCED LIQUID LOGIC, INC. (US) 2016-12-06 US claimed
US-20140246319-A1 DROPLET ACTUATORS AND TECHNIQUES FOR DROPLET-BASED ASSAYS ADVANCED LIQUID LOGIC, INC. (US) 2014-09-04 US claimed
WO-2013009927-A2 DROPLET ACTUATORS AND TECHNIQUES FOR DROPLET-BASED ASSAYS ADVANCED LIQUID LOGIC, INC. (US) 2013-01-17 WO claimed
US-20120315459-A1 CARBON NANOTUBE SHEET AND PROCESS FOR PRODUCTION THEREOF TAIYO NIPPON SANSO CORPORATION (JP) 2012-12-13 US claimed
WO-2005007895-A1 METHODS AND KITS FOR OBTAINING NUCLEIC ACID FROM BIOLOGICAL SAMPLES APPLERA CORPORATION (US) 2005-01-27 WO claimed
US-20050009036-A1 Methods and kits for obtaining nucleic acid from biological samples APPLERA CORPORATION (US) 2005-01-13 US claimed
US-12577543-B2 Method for producing polyisoprenoid by reaction catalyzed by mutant cis-prenyltransferase (CPT) family protein, and method for producing rubber product SUMITOMO RUBBER INDUSTRIES, LTD. (JP) 2026-03-17 US disclosed
US-20260002179-A1 METHOD FOR PRODUCING POLYISOPRENOID, VECTOR, TRANSFORMED PLANT, METHOD FOR PRODUCING PNEUMATIC TIRE, AND METHOD FOR PRODUCING RUBBER PRODUCT SUMITOMO RUBBER INDUSTRIES, LTD. (JP) 2026-01-01 US disclosed
US-12391964-B2 Method for producing polyisoprenoid, vector, transformed plant, method for producing pneumatic tire, and method for producing rubber product SUMITOMO RUBBER INDUSTRIES, LTD. (JP) 2025-08-19 US disclosed
WO-2025135104-A1 PEROVSKITE PRECURSOR SOLUTION, METHOD FOR MANUFACTURING SOLAR CELL, AND SOLAR CELL 株式会社カネカ 2025-06-26 WO disclosed
US-12257324-B2 Semiconductor SWCNT slurry for bioimaging and method for inspecting the same SHIMADZU CORPORATION (JP) 2025-03-25 US disclosed
EP-3586142-B1 DETECTION OF MEMBRANE PROTEINS UNIV OXFORD INNOVATION LTD (GB) 2024-12-25 EP disclosed
US-12146146-B2 Method for producing trans-polyisoprenoid, vector, transgenic plant, method for producing pneumatic tire and method for producing rubber product SUMITOMO RUBBER INDUSTRIES, LTD. (JP) 2024-11-19 US disclosed
US-20030061687-A1 High throughput screening of crystallization materials CALIFORNIA INSTITUTE OF TECHNOLOGY, A CALIFORNIA CORPORATION 2003-04-03 US disclosed
WO-2002056831-A9 IMMUNOGENIC PROTEOLIPOSOMES, AND USES THEREOF DANA FARBER CANCER INST INC (US) 2002-12-27 WO disclosed
WO-2002082047-A2 HIGH THROUGHPUT SCREENING OF CRYSTALLIZATION OF MATERIALS CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2002-10-17 WO disclosed
EP-1246607-A1 PROTEOLIPOSOMES CONTAINING AN INTEGRAL MEMBRANE PROTEIN HAVING ONE OR MORE TRANSMEMBRANE DOMAINS DANA-FARBER CANCER INSTITUTE, INC. (US) 2002-10-09 EP disclosed
WO-2002056831-A2 IMMUNOGENIC PROTEOLIPOSOMES, AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2002-07-25 WO disclosed
US-20010034432-A1 Proteoliposomes containing an integral membrane protein having one or more transmembrane domains DANA-FARBER CANCER INSTITUTE, INC. 2001-10-25 US disclosed
WO-2001049265-A1 PROTEOLIPOSOMES CONTAINING AN INTEGRAL MEMBRANE PROTEIN HAVING ONE OR MORE TRANSMEMBRANE DOMAINS DANA-FARBER CANCER INSTITUTE, INC. (US) 2001-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260002179-A1 METHOD FOR PRODUCING POLYISOPRENOID, VECTOR, TRANSFORMED PLANT, METHOD FOR PRODUCING PNEUMATIC TIRE, AND METHOD FOR PRODUCING RUBBER PRODUCT FNTB, FNTA, TPT1 SMPD1 3050/4885SLC25A20 1827/4885TP53 4013/4885
US-12577543-B2 Method for producing polyisoprenoid by reaction catalyzed by mutant cis-prenyltransferase (CPT) family protein, and method for producing rubber product FNTB, RTCB, PTAR1 SMPD1 3516/4885SLC25A20 2458/4885TP53 3876/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.